sb 203580 has been researched along with devazepide in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (devazepide) | Trials (devazepide) | Recent Studies (post-2010) (devazepide) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 780 | 5 | 42 |
| Protein | Taxonomy | sb 203580 (IC50) | devazepide (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 10 | |
| Cholecystokinin receptor type A | Rattus norvegicus (Norway rat) | 0.0009 | |
| Gastrin/cholecystokinin type B receptor | Rattus norvegicus (Norway rat) | 0.0008 | |
| Cholecystokinin receptor type A | Homo sapiens (human) | 0.0002 | |
| Gastrin/cholecystokinin type B receptor | Homo sapiens (human) | 0.245 | |
| Cholecystokinin receptor type A | Cavia porcellus (domestic guinea pig) | 0.27 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bergé, G; Carnazzi, E; Gagne, D; Galleyrand, JC; Ibarz, G; Martinez, J; Morel, C; Oiry, C | 1 |
1 other study(ies) available for sb 203580 and devazepide
| Article | Year |
|---|---|
Cross-interactions of two p38 mitogen-activated protein (MAP) kinase inhibitors and two cholecystokinin (CCK) receptor antagonists with the CCK1 receptor and p38 MAP kinase.
Topics: Adenosine Triphosphate; Animals; Benzodiazepinones; Binding Sites; Blotting, Western; COS Cells; Devazepide; Dose-Response Relationship, Drug; Enzyme Inhibitors; Genes, Reporter; Hormone Antagonists; Imidazoles; Immunoblotting; Inositol Phosphates; Kinetics; Ligands; MAP Kinase Signaling System; Models, Chemical; Models, Molecular; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Protein Binding; Protein Conformation; Pyridines; Rats; Receptor, Cholecystokinin A; Receptors, Cholecystokinin; Signal Transduction; Time Factors; Transfection | 2005 |